AR021757A1 - Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3 - Google Patents

Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3

Info

Publication number: AR021757A1
Authority: AR; Argentina
Prior art keywords: group; type; hydrogen; androstan; alkyl
Prior art date: 1998-08-07

Application number

ARP990103961A

Other languages

English (en)

Spanish (es)

Original Assignee

Endorech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-07

Filing date

1999-08-06

Publication date

2002-08-07

1999-08-06 Application filed by Endorech Inc filed Critical Endorech Inc

2002-08-07 Publication of AR021757A1 publication Critical patent/AR021757A1/es

Links

239000003112 inhibitor Substances 0.000 title abstract 5
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 4
238000006243 chemical reaction Methods 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 title abstract 2
229960003473 androstanolone Drugs 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
229960003604 testosterone Drugs 0.000 title abstract 2
101710088194 Dehydrogenase Proteins 0.000 title 1
230000000694 effects Effects 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 6
239000001257 hydrogen Substances 0.000 abstract 6
150000002431 hydrogen Chemical class 0.000 abstract 5
101710172561 3alpha-hydroxysteroid dehydrogenase Proteins 0.000 abstract 3
102100036504 Dehydrogenase/reductase SDR family member 9 Human genes 0.000 abstract 3
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
150000001408 amides Chemical class 0.000 abstract 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
230000005764 inhibitory process Effects 0.000 abstract 2
150000002576 ketones Chemical group 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
239000001301 oxygen Substances 0.000 abstract 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
102000012394 17beta-dehydrogenases Human genes 0.000 abstract 1
108050002933 17beta-dehydrogenases Proteins 0.000 abstract 1
201000004384 Alopecia Diseases 0.000 abstract 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
229940124186 Dehydrogenase inhibitor Drugs 0.000 abstract 1
206010020112 Hirsutism Diseases 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
229940124139 Hydroxysteroid dehydrogenase inhibitor Drugs 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
206010039792 Seborrhoea Diseases 0.000 abstract 1
125000004423 acyloxy group Chemical group 0.000 abstract 1
125000003302 alkenyloxy group Chemical group 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
201000002996 androgenic alopecia Diseases 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
125000001246 bromo group Chemical group Br* 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000001153 fluoro group Chemical group F* 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
-1 nitro, hydroxyl Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
201000007094 prostatitis Diseases 0.000 abstract 1
208000008742 seborrheic dermatitis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ARP990103961A 1998-08-07 1999-08-06 Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3 AR021757A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9562398P	1998-08-07	1998-08-07

Publications (1)

Publication Number	Publication Date
AR021757A1 true AR021757A1 (es)	2002-08-07

Family

ID=22252842

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP990103961A AR021757A1 (es)	1998-08-07	1999-08-06	Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3

Country Status (9)

Country	Link
EP (1)	EP1102582A2 (fr)
JP (1)	JP2002522380A (fr)
CN (1)	CN1322130A (fr)
AR (1)	AR021757A1 (fr)
AU (1)	AU5144999A (fr)
CA (1)	CA2339368A1 (fr)
ID (1)	ID28791A (fr)
NO (1)	NO20010651L (fr)
WO (1)	WO2000007576A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5504074A (en)	1993-08-06	1996-04-02	Children's Medical Center Corporation	Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en)	1993-08-06	2005-06-21	The Children's Medical Center Corporation	Estrogenic compounds as anti-mitotic agents
EP1321146A3 (fr) *	1998-03-11	2004-06-02	Endorecherche Inc.	Inhibiteurs de la 17beta-hydroxysteroide deshydrogénase du type 5 et du type 3 ainsi que leurs méthodes d'utilisation
US7087592B1 (en)	1999-08-23	2006-08-08	Entre Med, Inc.	Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6891953B1 (en)	2000-06-27	2005-05-10	Microsoft Corporation	Method and system for binding enhanced software features to a persona
US7135581B2 (en)	2000-08-18	2006-11-14	Entremed, Inc.	Antiangiogenic agents
US6995278B2 (en) *	2000-08-18	2006-02-07	Entre Med, Inc.	Antiangiogenic agents
AU2001288386B2 (en) *	2000-11-27	2006-11-02	Entremed, Inc.	2-substituted estrogens as antiangiogenic agents
US6710037B2 (en) *	2001-05-01	2004-03-23	Schering Corporation	Method of treating androgen-dependent disorders
DE60239207D1 (de) *	2001-08-10	2011-03-31	Takeda Pharmaceutical	Gnrh-agonistische kombinationsmittel
US7524866B2 (en)	2001-11-29	2009-04-28	Gtx, Inc.	Prevention and treatment of androgen—deprivation induced osteoporosis
MXPA04005112A (es) *	2001-11-29	2005-04-29	Gtx Inc	Prevencion y tratamiento de osteoporosis inducida por privacion de androgeno.
JP2006526025A (ja)	2003-05-28	2006-11-16	エントレメッドインコーポレイテッド	抗血管新生剤
US7498322B2 (en)	2004-03-12	2009-03-03	Entremed, Inc.	Antiangiogenic agents
US7419972B2 (en)	2004-07-02	2008-09-02	Schering Ag	2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
DE102004032674A1 (de) *	2004-07-02	2006-01-26	Schering Ag	Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
WO2007109312A2 (fr)	2006-03-20	2007-09-27	Entremed, Inc.	2-méthoxyestradiol présentant une activité anti-arthritique pouvant modifier l'évolution de la maladie
US9284345B2 (en) *	2007-04-12	2016-03-15	Endorecherche, Inc.	17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US8513422B2 (en) *	2007-08-31	2013-08-20	Astellas Pharma Inc.	Piperidine derivative
CN101698834B (zh) *	2009-09-08	2012-05-23	北京利德曼生化股份有限公司	3α-羟基类固醇脱氢酶及其核苷酸序列、重组载体、重组宿主细胞和试剂盒
US9512169B2 (en) *	2012-07-10	2016-12-06	Bayer Pharma Aktiengesellschaft	3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
EA201500851A1 (ru) *	2013-02-21	2016-02-29	Байер Фарма Акциенгезельшафт	ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
CN104873520A (zh) *	2014-02-27	2015-09-02	天津药物研究院	一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途
CN104873525A (zh) *	2014-02-27	2015-09-02	天津药物研究院	一种11β-羟基类固醇脱氢酶抑制剂及其药用组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3562260A (en) *	1965-08-23	1971-02-09	Ormonoterapia Richter Spa	2-carbonyl-estratrienes and method of their preparation
US4340602A (en) *	1978-10-18	1982-07-20	Wayne State University	Compositions inhibiting estrogen sulfotransferase activity
GB2135189B (en) *	1983-02-22	1986-07-09	Joachim Georg Liehr	Estrogen deficiency conditioned with 2-fluoroestradiols
US4568673A (en) *	1984-03-20	1986-02-04	Wayne State University	Compositions inhibiting murine MXT ductal carcinoma
US5504074A (en) *	1993-08-06	1996-04-02	Children's Medical Center Corporation	Estrogenic compounds as anti-angiogenic agents
TR200002784T2 (tr) *	1998-03-11	2000-12-21	Endorecherche, Inc	Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar

1999
- 1999-08-06 AR ARP990103961A patent/AR021757A1/es unknown
- 1999-08-06 EP EP99936218A patent/EP1102582A2/fr not_active Withdrawn
- 1999-08-06 WO PCT/CA1999/000724 patent/WO2000007576A2/fr not_active Ceased
- 1999-08-06 ID IDW20010531A patent/ID28791A/id unknown
- 1999-08-06 CA CA002339368A patent/CA2339368A1/fr not_active Abandoned
- 1999-08-06 JP JP2000563261A patent/JP2002522380A/ja active Pending
- 1999-08-06 AU AU51449/99A patent/AU5144999A/en not_active Abandoned
- 1999-08-06 CN CN99811739A patent/CN1322130A/zh active Pending
2001
- 2001-02-07 NO NO20010651A patent/NO20010651L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2339368A1 (fr)	2000-02-17
EP1102582A2 (fr)	2001-05-30
WO2000007576A2 (fr)	2000-02-17
NO20010651L (no)	2001-04-05
JP2002522380A (ja)	2002-07-23
CN1322130A (zh)	2001-11-14
AU5144999A (en)	2000-02-28
ID28791A (id)	2001-07-05
WO2000007576A3 (fr)	2000-03-30
NO20010651D0 (no)	2001-02-07

Publication	Publication Date	Title
AR021757A1 (es)	2002-08-07	Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3
MY157898A (en)	2016-08-15	Helix 12 directed steroidal pharmaceutical products
DK1480634T3 (da)	2011-11-14	Selektive androgenreceptormodulatorer (SARM) til behandling af benign prostatahyperplasi
TNSN07473A1 (en)	2009-03-17	Helix 12 directed non-steroidal antiandrogens
HUT60139A (en)	1992-08-28	Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen
BR9908592A (pt)	2001-04-24	Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
PT1019060E (pt)	2007-10-03	Inibidores da síntese de adrogénio
PL338885A1 (en)	2000-11-20	Combination of thyrisinic kinase inhibitor and pharmacological castration for treating prostatic carcinoma
MX9304541A (es)	1994-05-31	Esteriodes de 17-espirometileno.
MY131522A (en)	2007-08-30	PHARMACEUTICAL COMPOSITION AND USES FOR ANDROST-5-ENE-3ß,17ß-DIOL
DE69125714D1 (de)	1997-05-22	Zusammensetzung für die behandlung des humanen prostata adenokarzinom
PE20060379A1 (es)	2006-05-27	Derivados de 4-cicloalcoxibenzonitrilos como moduladores de androgenos
EP1515754A4 (fr)	2007-06-20	La beta-2-glycoproteine 1 est un inhibiteur de l'angiogenese
WO2001017479A3 (fr)	2001-09-20	Methodes et compositions pour prevenir et traiter les troubles de la prostate
WO2001022919A3 (fr)	2002-07-11	Derives de spiro[azacycloalkyle et cycloalkyle bicycliques] et utilisations de ceux-ci
Kirby	1996	Recent advances in the medical management of prostate cancer
DE69519728D1 (de)	2001-02-01	17 beta-aryl-4-aza-steroidderivate
Sun et al.	2011	A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia
MX2025009867A (es)	2025-09-02	Metodos para el tratamiento de cancer de mama
Mahler et al.	1990	Clinical profile of a new non-steroidal antiandrogen
NZ327041A (en)	1999-11-29	17-beta-cyclopropyl(amino/oxy) 4-aza steriods as active inhibitors of testosterone 5-alpha-reductase and C17-20-lyase
Cabeza et al.	2001	New progesterone esters as 5α-reductase inhibitors
Garg et al.	2006	Management of benign prostate hyperplasia: An overview of α-adrenergic antagonist
ES2149984T3 (es)	2000-11-16	Derivados imidazolilalquilos de imidazol(5,1-c)(1,4)benzoxazin-1-ona y su utilizacion como agentes terapeuticos.
Celasco et al.	2005	Pharmacological profile of 9, 11-dehydrocortexolone 17α-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity